Literature DB >> 30868436

Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation.

Lee S Nguyen1,2, Mathieu Vautier3, Yves Allenbach3, Noel Zahr4, Olivier Benveniste3, Christian Funck-Brentano4, Joe-Elie Salem4.   

Abstract

Inhibitors of mechanistic target of rapamycin (mTOR inhibitors) are used as antiproliferative immunosuppressive drugs and have many clinical applications in various drug combinations. Experience in transplantation studies has been gained regarding the side effect profile of these drugs and the potential benefits and limitations compared with other immunosuppressive agents. This article reviews the adverse effects of mTOR inhibitors in solid organ transplantation, with special attention given to mechanisms hypothesized to cause adverse events and their management strategies.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30868436     DOI： 10.1007/s40264-019-00810-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


  26 in total

1.  Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis.

Authors:  Chun-Hung Lin; Chia-Ter Chao; Mei-Yi Wu; Wei-Cheng Lo; Tsu-Chen Lin; Mai-Szu Wu
Journal:  Int Urol Nephrol       Date:  2019-10-01       Impact factor: 2.370

Review 2.  Metabolic Communication and Healthy Aging: Where Should We Focus Our Energy?

Authors:  Hannah J Smith; Arpit Sharma; William B Mair
Journal:  Dev Cell       Date:  2020-07-02       Impact factor: 12.270

3.  mTOR-Dependent Autophagy Regulates Slit Diaphragm Density in Podocyte-like Drosophila Nephrocytes.

Authors:  Dominik Spitz; Maria Comas; Lea Gerstner; Séverine Kayser; Martin Helmstädter; Gerd Walz; Tobias Hermle
Journal:  Cells       Date:  2022-07-02       Impact factor: 7.666

4.  Case Report: Reversible Hyperglycemia Following Rapamycin Treatment for Atypical Choroid Plexus Papilloma in an Infant.

Authors:  Jiale Liu; Minjie Luo; Siyuan Lv; Shaohua Tao; Zhu Wu; Lihua Yu; Danna Lin; Lulu Huang; Li Wu; Xu Liao; Juan Zi; Xiaorong Lai; Yuting Yuan; Wangming Zhang; Lihua Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-05       Impact factor: 6.055

5.  [The dual mTORC1/2 inhibitor AZD2014 inhibits acute graft rejection in a rat liver transplantation model].

Authors:  H Liao; Y Wang; X Xu; C Zhou; J Zhang; K Zhong; D Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-04-20

6.  mTORC1 Deficiency Modifies Volume Homeostatic Responses to Dietary Sodium in a Sex-Specific Manner.

Authors:  Danielle L Brooks; Amanda E Garza; Ezgi Caliskan Guzelce; Shadi K Gholami; Thitinan Treesaranuwattana; Stephen Maris; Sanjay Ranjit; Chee Sin Tay; Jessica M Lee; Jose R Romero; Gail K Adler; Luminita H Pojoga; Gordon H Williams
Journal:  Endocrinology       Date:  2020-05-01       Impact factor: 4.736

7.  Integrative multiplatform-based molecular profiling of human colorectal cancer reveals proteogenomic alterations underlying mitochondrial inactivation.

Authors:  Wei Zhang; Donge Tang; Liewen Lin; Tingting Fan; Ligang Xia; Wanxia Cai; Weier Dai; Chang Zou; Lianghong Yin; Yong Xu; Yong Dai
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 8.  Calcium pyrophosphate deposition (CPPD) in a liver transplant patient: are hypomagnesemia, tacrolimus or both guilty? A case-based literature review.

Authors:  Simon Cadiou; Antonia Le Gruyer; Baptiste Giguet; François Robin; Morgane Milin; Xavier Guennoc; Pascal Guggenbuhl; Marine De Saint-Riquier
Journal:  Rheumatol Int       Date:  2021-03-11       Impact factor: 2.631

9.  Patients with Congenital Low-Flow Vascular Malformation Treated with Low Dose Sirolimus.

Authors:  Veroniek E M Harbers; Gerard A P J M Rongen; Carine J M van der Vleuten; Bas H Verhoeven; Peter C J de Laat; Chantal M A M van der Horst; Willemijn M Klein; Leo J Schultze Kool; D Maroeska W M Te Loo
Journal:  Adv Ther       Date:  2021-05-18       Impact factor: 3.845

10.  mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.

Authors:  Jose-Alberto Palma; Jose Martinez; Patricio Millar Vernetti; Thong Ma; Miguel A Perez; Judy Zhong; Yingzhi Qian; Suman Dutta; Katherine N Maina; Ibrar Siddique; Gal Bitan; Benjamin Ades-Aron; Timothy M Shepherd; Un J Kang; Horacio Kaufmann
Journal:  Mov Disord       Date:  2022-01-18       Impact factor: 9.698
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.